U.S. officials are already grappling with the thorny question of who should be first in line once a coronavirus vaccine is available
Initial supplies of any successful coronavirus vaccines are now expected to fall short of what is needed even for high-priority groups like health-care workers, forcing drugmakers and U.S. officials to grapple with the thorny question of who should be first in line.
Public-health officials estimate more than 100 million Americans, including doctors and nurses, other essential workers and nursing-home residents, should get vaccinated before the general public because they are at greater risk of exposure to the virus or of contracting...
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novavax's coronavirus vaccine generates promising immune response in early trial, data showsNovavax's potential vaccine to prevent Covid-19 generated a promising immune response in an early-stage clinical trial, the U.S.-based biotech firm announced Tuesday.
Weiterlesen »
Novavax coronavirus vaccine induces immune response in early study, shares jumpNovavax Inc said on Tuesday its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10%.
Weiterlesen »
US expects millions of coronavirus vaccine doses by early next yearThe top US infectious diseases Anthony Fauci says drugmakers will likely have tens of millions of doses of coronavirus vaccines in the early part of next year, with production ramping up to a billion doses by the end of 2021.
Weiterlesen »
Here Are The Early-Opening U.S. School Districts Already Battling Cases Of The CoronavirusAs the debate on how best to reopen U.S. schools this fall amid the pandemic continues, some school districts that have resumed classes this summer are already grappling with coronavirus cases, forcing students and staff to quarantine.
Weiterlesen »
Novavax becomes fifth COVID-19 vaccine developer to release promising early results'Good news,' said Dr. William Schaffner, a professor and infectious disease expert at the Vanderbilt University School of Medicine. 'I think it clearly boosts confidence that we will have one or more vaccines.'
Weiterlesen »
Novavax becomes fifth COVID-19 vaccine developer to release promising early resultsThe candidate vaccine seems to have generated an immune reaction similar to those in people who have recovered from COVID-19, the data shows.
Weiterlesen »